Moderna (MRNA) is holding onto the big gains it made after it was announced that its personalized vaccine candidate reduces the risk of melanoma recurrence or death by 44% when given to patients in combination with Merck’s (MRK) Keytruda.
I am recommending we roll our put out two weeks to generate more income while lowering our strike price to reduce risk.
Let’s also roll our SPDR S&P Biotech ETF (XBI) put out two weeks to generate more income and reduce our net debit on the position. If the sector holds up, we could exit the position soon around breakeven.
You can enter the second leg of today’s trades even if you were not in the previous ones. Just be aware that we will be managing and tracking them based on the ongoing positions.
MRNA Dec Week Four (12/23) 190 Put
Current Stock Price: $207.98
Net Debit: $23.65
Action:
- Buy to close the MRNA Dec Week Four (12/23) 190 Put for around $0.19
- Sell to open the MRNA Jan Week One (1/6) 180 Put for around $1.29
- Set initial credit limit at $1.10, but adjust as needed to roll today
New Net Debit: $22.55
XBI Dec Week Four (12/23) 80 Put
Current Stock Price: $82.93
Net Debit: $1.30
Action:
- Buy to close the XBI Dec Week Four (12/23) 80 Put for around $0.13
- Sell to open the XBI Jan Week One (1/6) 80 Put for around $1.03
- Set initial credit limit at $0.90, but adjust as needed to roll today
New Net Debit: $0.40